Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Want to cut your energy bills? Here’s how five experts are doing it 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March. Details of the presentations are as follows:
| Cowen & Company 37th Annual Healthcare Conference | |||
| Date: | Monday, March 6, 2017 | ||
| Time: | 2:40 p.m. ET | ||
| Location: | Boston | ||
| Barclays Global Healthcare Conference 2017 | |||
| Date: | Thursday, March 16, 2017 | ||
| Time: | 9:30 a.m. ET | ||
| Location: | Miami | ||
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. Archived replays will be available for approximately 30 days following the respective presentations.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
